Based on this systematic review of the literature and subtype-specific analysis, it is reasonable for individual tumour boards to consider de-escalation of breast surgery in carefully selected patients with extensive co-existent DCIS showing excellent response to NST especially in patients with HER2 positive and triple negative breast cancer. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.